Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCHW) Cash from Investing Activities (2021 - 2025)

Envoy Medical recorded quarterly Cash from Investing Activities of -$172000.0 in Q4 2025, down 17100.0% quarter-over-quarter from -$1000.0 in Q2 2025, and down 132.21% year-over-year from $534000.0 in Q4 2024.

Envoy Medical's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$172000.0 for Q4 2025.

  • In Q4 2025, Cash from Investing Activities fell 132.21% year-over-year to -$172000.0; the TTM figure through Dec 2025 stood at -$179000.0 (up 81.73% YoY), while the FY2025 annual figure was -$179000.0, up 81.73% from the prior year.
  • Cash from Investing Activities came in at -$172000.0 for Q4 2025 at Envoy Medical, down from -$1000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $534000.0 in Q4 2024 to a low of -$420.0 million in Q1 2021.
  • A 5-year average of -$30.5 million and a median of -$60500.0 in 2023 frame the typical range for Cash from Investing Activities.
  • On a YoY basis, Cash from Investing Activities climbed as much as 2642.86% in 2024 and fell as far as 7081.82% in 2024.
  • Envoy Medical's Cash from Investing Activities stood at -$5.0 million in 2021, then surged by 99.18% to -$41000.0 in 2022, then soared by 48.78% to -$21000.0 in 2023, then jumped by 2642.86% to $534000.0 in 2024, then slumped by 132.21% to -$172000.0 in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered -$172000.0, -$1000.0, and -$6000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -20.32 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -185.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -816.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -591.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -92.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -475.32 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -298.50 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -2.50 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -217.20 Mn
10 Envoy Medical - - -274,000.00 -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -172,000.00
Dec 31, 2025 -172,000.00
Jun 30, 2025 -1,000.00
Jun 30, 2025 -1,000.00
Mar 31, 2025 -6,000.00
Mar 31, 2025 -6,000.00
Dec 31, 2024 534,000.00
Dec 31, 2024 534,000.00
Sep 30, 2024 -615,000.00
Sep 30, 2024 -615,000.00
Jun 30, 2024 -790,000.00
Jun 30, 2024 -790,000.00
Mar 31, 2024 -109,000.00
Mar 31, 2024 -109,000.00
Dec 31, 2023 -21,000.00
Dec 31, 2023 -21,000.00
Sep 30, 2023 -62,000.00
Sep 30, 2023 -62,000.00
Jun 30, 2023 -11,000.00
Jun 30, 2023 -11,000.00
Mar 31, 2023 -59,000.00
Mar 31, 2023 -59,000.00
Dec 31, 2022 -41,000.00
Dec 31, 2022 -41,000.00
Jun 30, 2021 -5.00 Mn
Jun 30, 2021 -5.00 Mn
Mar 31, 2021 -420.00 Mn
Mar 31, 2021 -420.00 Mn